Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 9:09 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 1,144 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Grippe Clear all

Conditions: Influenza, Collaboration
Interventions: Private/public collaboration to increase flu vaccination, Usual care; Behavioral · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 6 Months to 18 Years
Enrollment: 117,175 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2015
U.S. locations: 27
States / cities: Aurora, Colorado • Brighton, Colorado • Broomfield, Colorado + 15 more

Conditions: Influenza
Interventions: Trivalent inactivated influenza vaccine, Trivalent Baculovirus-expressed Influenza HA vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Influenza
Interventions: Inactivated Influenza H1N1 vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 64 Years
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 6
States / cities: Iowa City, Iowa • Baltimore, Maryland • St Louis, Missouri + 3 more

Conditions: Influenza
Interventions: CSL Trivalent Inactivated Influenza Vaccine - Thimerosal-free, CSL Trivalent Inactivated Influenza Vaccine with Thimerosal, Placebo with Thimerosal; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 64 Years
Enrollment: 1,359 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 10
States / cities: Stanford, California • Iowa City, Iowa • Baltimore, Maryland + 7 more

Conditions: Influenza, Swine-origin A/H1N1 Influenza
Interventions: Monovalent Subvirion A/H1N1 influenza vaccine with adjuvant, Monovalent Subvirion A/H1N1 influenza vaccine, Normal saline solution; Biological
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 548 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 15
States / cities: Anaheim, California • Fountain Valley, California • South Miami, Florida + 11 more

Conditions: Immune Defect
Interventions: Fluzone Quadrivalent; Biological
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 60 Years
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Critically Ill Renal Failure Requiring CVVHD and Oseltamivir, Critically Ill Requiring ECMO and Oseltamivir
Interventions: pharmacokinetic blood sampling, pharmacokinetic blood and dialysate sampling; Procedure
Lead sponsor: University of Michigan; Other
Eligibility: Not listed
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Influenza, Human
Interventions: FLU Q-PAN H5N8 375_B, FLU Q-PAN H5N8 375_A, FLU Q-PAN H5N8 750_B, FLU Q-PAN H5N8 750_A; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 518 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 20
States / cities: Anniston, Alabama • Mobile, Alabama • Tempe, Arizona + 17 more

Conditions: Influenza Vaccine
Interventions: Cam2020 M2SR H3N2 influenza vaccine, Fluzone HD IIV, IN Placebo, IM Placebo; Biological · Other
Lead sponsor: FluGen Inc; Industry
Eligibility: 65 Years to 85 Years
Enrollment: 303 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 6
States / cities: Port Orange, Florida • Meridian, Idaho • Lenexa, Kansas + 3 more

Conditions: Influenza -Like Illness, Influenza A, Influenza Type B, Respiratory Viral Infection, Respiratory Tract Infections
Interventions: Not listed
Lead sponsor: Evidation Health; Industry
Eligibility: 18 Years and older
Enrollment: 5,233 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: San Mateo, California

Conditions: Influenza, Hepatitis A, Typhoid, Healthy Adults
Interventions: Fluzone® quadrivalent, Fluzone High Dose, Fluad, Vaqta, Typhim Vi, Vivotif; Biological
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Stanford, California

Conditions: Influenza
Interventions: Influenza Virus Vaccine USP Quadrivalent, (Zonal Purified Subvirion) 2012 2013 Formulation, Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone Intradermal; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 3,360 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 38
States / cities: Hoover, Alabama • Huntsville, Alabama • Chandler, Arizona + 32 more

Conditions: Influenza, Vaccination, Health Promotion, Health Behavior
Interventions: Reminder, Financial incentive, Lottery; Behavioral
Lead sponsor: National Bureau of Economic Research, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 57,581 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Danville, Pennsylvania

Conditions: 2009 H1N1 Influenza Virus
Interventions: 2009 H1N1 Virus Vaccine; Biological
Lead sponsor: University of Rochester; Other
Eligibility: 60 Years and older
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2010
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Influenza
Interventions: VAX161C vaccine; Biological
Lead sponsor: VaxInnate Corporation; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 275 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 2
States / cities: South Miami, Florida • Lenexa, Kansas

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Fluzone; Biological
Lead sponsor: Banner Health; Other
Eligibility: 50 Years to 64 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Influenza
Interventions: FluMist; Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 5 Years to 49 Years
Enrollment: 345 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 11
States / cities: Miami, Florida • Chicago, Illinois • Bardstown, Kentucky + 8 more

Conditions: Seasonal Influenza
Interventions: mRNA-1011.1, mRNA-1011.2, mRNA-1012.1, mRNA-1010, mRNA-1010.2, mRNA-1010.3; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 50 Years to 75 Years
Enrollment: 698 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 22
States / cities: Lakewood, California • Long Beach, California • Fort Collins, Colorado + 19 more

Conditions: Influenza
Interventions: DCVC H1 HA mRNA vaccine, Quadrivalent Recombinant Seasonal Influenza Vaccine, Sodium Chloride, 0.9%; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Influenza
Interventions: Baloxavir Marboxil; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 3 Weeks to 11 Years
Enrollment: 1,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 28
States / cities: Birmingham, Alabama • Harrisburg, Arkansas • Miami, Florida + 23 more

Conditions: Seasonal Influenza
Interventions: VXA-A1.1; Biological
Lead sponsor: Vaxart; Industry
Eligibility: 18 Years to 49 Years · Male only
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Influenza
Interventions: CAIV-T, TIV, Placebo; Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001
U.S. locations: 1
States / cities: Stamford, Connecticut

Conditions: Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Waldenstrom Macroglobulinemia, Lymphocytosis, Lymphoma, Non-Hodgkin, B-Cell Chronic Lymphocytic Leukemia, Hematological Malignancies
Interventions: Not listed
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2025
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Influenza, Human+COVID-19
Interventions: Investigational mRNA Seasonal Flu/COVID-19 Combination (Flu/COVm) Vaccine, Licensed Seasonal Influenza Vaccine, Licensed COVID-19 Vaccine; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 65 Years to 85 Years
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 12
States / cities: Anniston, Alabama • Little Rock, Arkansas • Fair Oaks, California + 9 more

Search by objective public record fields.

Collaborative Efforts to Increase Flu Vaccination

High Dose Influenza in Immunosuppressed Subjects

H1N1 Vaccine at Two Dose Levels in HIV Positive Adults

Immunogenicity, Safety and Tolerability of CSL Limited Inactivated Influenza Vaccine in Adults

A Study of Different Formulations of an Adjuvanted A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly

Opioid, HIV and Immune System

Pharmacokinetics of Tamiflu® (Oseltamivir) in Patients Receiving Extracorporeal Membrane Oxygenation (ECMO)and or Continuous Venovenous Hemodialysis (CVVHD)

Safety and Immunogenicity of Different Formulations of Monovalent Influenza A/Astrakhan/3212/2020 Like (H5N8) Virus Vaccine With AS03 Adjuvant System in Medically Stable Adults

Safety and Immunogenicity of Cam2020 M2SR H3N2 Monovalent Influenza Vaccine Alone or With Licensed IIV in Older Adults

Home Testing of Respiratory Illness

Effects of Aging on Primary and Secondary Vaccine Responses

Study of Intradermal Quadrivalent Influenza Vaccine in Adults Aged 18 Through 64 Years

Lottery Incentive Nudges to Increase Influenza Vaccinations

Effects of Age on Response to the 2009 H1N1 Virus Vaccine

Study of the Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49

Seasonal Influenza Vaccine, Quadrivalent Versus Trivalent in Patients With Advanced Chronic Obstructive Pulmonary Disease

Trial to Assess the Shedding,Immunogenicity, and Safety of FluMist Administered to Healthy Individuals 5-49 Years of Age

A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults

A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults

A Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts

Immunogenicity of Seasonal Influenza by Delivery Directly to Ileum

Phase II Study to Investigate the Kinetics of the Immune Response Generated by Influenza Virus Vaccine.

B-Cell Hematologic Malignancy Vaccination Registry

A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults